| Market Capitalization (Millions $) |
5,719 |
| Shares
Outstanding (Millions) |
83 |
| Employees |
991 |
| Revenues (TTM) (Millions $) |
827 |
| Net Income (TTM) (Millions $) |
-187 |
| Cash Flow (TTM) (Millions $) |
-645 |
| Capital Exp. (TTM) (Millions $) |
301 |
Business Description
Ptc Therapeutics Inc is a publicly traded biopharmaceutical company headquartered in South Plainfield, New Jersey, USA. The company has a focus on the discovery, development, and commercialization of innovative medicines to treat rare diseases. Ptc Therapeutics Inc is a pioneer in the field of RNA biology, with a particular emphasis on identifying small molecules that can modulate RNA activity.
The company is best known for its groundbreaking work in developing Ataluren or Translarna, an oral medication, for treating Duchenne muscular dystrophy (DMD) caused by a nonsense mutation. The drug has also been approved by the European Commission and is marketed under the name Translarna. The company also has several other pipeline products under development, targeting various rare genetic disorders.
The company was founded in 1998 as PTC Therapeutics, Inc. by Stuart W. Peltz, Ph.D., and he acted as the CEO of the company from its inception. The company went public in 2013 and is now traded on the NASDAQ Stock Exchange (PTCT).
Ptc Therapeutics has grown rapidly over the years through strategic acquisitions and collaborations. The company's strategic partners include Roche, Biogen IDEC, Genzyme, and AstraZeneca. Ptc Therapeutics is also involved in various collaborations with academic institutions and government agencies to advance research in RNA biology and therapy.
Ptc Therapeutics actively participates in philanthropic efforts, including partnering with organizations such as Parent Project Muscular Dystrophy, a non-profit organization aimed at finding a cure for Duchenne muscular dystrophy.
In conclusion, Ptc Therapeutics Inc is a pioneering biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for rare genetic disorders. The company's innovative work in RNA biology has led to the development of groundbreaking therapeutics for DMD and several other rare diseases. The company continues to pursue its goal of advancing research and development in RNA therapeutics, collaborating with academic institutions, government agencies, and non-profit organizations to find cures for rare genetic diseases.
Company Address: 500 Warren Corporate Center Drive Warren 7059 NJ
Company Phone Number: 222-7000 Stock Exchange / Ticker: NASDAQ PTCT
|
0.38% 
50.09 %